Literature DB >> 9108455

Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo.

M S Dilber1, M R Abedi, B Christensson, B Björkstrand, G M Kidder, C C Naus, G Gahrton, C I Smith.   

Abstract

Transfer of the herpes simplex thymidine kinase gene (HSVtk) into tumor cells followed by the administration of ganciclovir (GCV) provides a potential strategy for the treatment of some malignancies. During GCV treatment, not only the cells that express the HSVtk gene are killed but also frequently neighboring tumor cells that are not genetically altered. This has been called the "bystander effect." Although the mechanism of the bystander effect in vivo remains elusive, our results suggest that gap junction formation between neighboring cells is an important contributing factor. The C6 rat glioma cell line, which exhibits a low level of intercellular communication by gap junctions and connexin43 (Cx43)-transfected clones of this cell line forming gap junctions from a moderate level (Cx43-12 and Cx43-14) to a high level (Cx43-13), were transduced with HSVtk. Transduced and nontransduced cells were mixed in various concentrations and then cultured in vitro or injected s.c. into C.B-17/SCID-beige mice followed by i.p. injections of GCV. Cx43-transfected clones showed a significant increase of the bystander effect compared with the less coupled C6 parental cell line. In 11 of 12 mice injected with cells of Cx43-transfected clones, no tumors were seen at the inoculation site when a mixture of 50% HSVtk-negative and HSVtk-positive cells was used. Moreover, in mice injected with cells of clone Cx43-13, which exhibits the highest intercellular communication, tumors were frequently undetectable at the inoculation site when using mixtures of 75% HSVtk-negative and 25% HSVtk-positive cells, and even mixtures containing 5% HSVtk-positive cells of Cx43-transfected clones showed tumor size reduction. All animals in control groups (n = 26) developed large tumors at every injection site. These results demonstrate that gap junctions are an important component in mediating the bystander effect in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108455

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Disruption of gap junctions attenuates aminoglycoside-elicited renal tubular cell injury.

Authors:  Jian Yao; Tao Huang; Xin Fang; Yuan Chi; Ying Zhu; Yigang Wan; Hiroyuki Matsue; Masanori Kitamura
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 3.  The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system.

Authors:  Eliseo A Eugenin; Daniel Basilio; Juan C Sáez; Juan A Orellana; Cedric S Raine; Feliksas Bukauskas; Michael V L Bennett; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-23       Impact factor: 4.147

Review 4.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 6.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

7.  Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter.

Authors:  C E Badr; J M Niers; D Morse; J A Koelen; P Vandertop; D Noske; T Wurdinger; P A Zalloua; B A Tannous
Journal:  Gene Ther       Date:  2010-12-09       Impact factor: 5.250

8.  Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Authors:  Donna N Douglas; Toshiyasu Kawahara; Banu Sis; David Bond; Karl P Fischer; D Lorne J Tyrrell; Jamie T Lewis; Norman M Kneteman
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

Review 9.  Stem cells as cellular vehicles for gene therapy against glioblastoma.

Authors:  Wei Wang; Fanlong Liu; Bingyu Xiang; Charlie Xiang; Xiaozhou Mou
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.

Authors:  A Ardiani; M Sanchez-Bonilla; M E Black
Journal:  Cancer Gene Ther       Date:  2009-09-18       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.